Navigation Links
Interim Analysis of Data from e-HEALING Registry of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Date:11/7/2008

Sigmund Silber to Highlight 12-Month Patient Subset Results in Oral

Presentation

HONG KONG, Nov. 7 /PRNewswire/ -- An interim analysis of 12-month patient subset data from e-HEALING, a global post-marketing surveillance registry of OrbusNeich's Genous Bio-engineered R stent, will be presented next week at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans.

Sigmund Silber, M.D., F.A.C.C., F.E.S.C., a professor of medicine with the Cardiology Practice and Hospital, Munich, will present the data at 9:30 a.m. CST on Nov. 12 in Auditorium C at the Ernest N. Morial Convention Center. Silber and Robbert de Winter, M.D., Ph.D., F.E.S.C., a professor of medicine with the Academic Medical Center, Amsterdam, are the co-principal investigators of e-HEALING.

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients treated with the Genous Bio-engineered R stent. The study protocol recommends that patients receive one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary endpoint of the registry is target vessel failure at 12 months.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progeni
'/>"/>

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
2. Misonix Announces Interim Distribution Agreement for Italy
3. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
4. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
5. Arpida Reports Interim Results for Six Months to 30 June 2008
6. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
7. LPBP Inc. - Re-filing certification of interim filings
8. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
9. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
10. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
11. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... researchers from the University of Leicester has furthered ... the potential to create new materials using nanosized ... published in the prestigious academic journal Physical ... to examine in rich detail the structure and ... an acetylene molecule and a single helium atom. ...
(Date:7/25/2014)... July 25, 2014 WABC Radio show out ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s ... stem cell therapy in pets. Dr. Harman first visited ... stem cell therapy for pets suffering from osteoarthritis and other ... Veterinary Medicine industry forward. , Young has invited Dr. Harman ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... Citizens unite to support the upcoming San, Diego FAAN Walk to ... ... Park at 9:00 a.m., FAIRFAX, Va. and SAN DIEGO, Oct. 4 ... a,world leader in information about food allergies, and Verus,Pharmaceuticals, Inc., a San ...
... Hyperion,Therapeutics, Inc., a privately-held biopharmaceutical company ... and hepatology,therapies that address underserved patient populations ... management appointments and closing of up,to $15 ... and Life Sciences,Capital. Joining Co-Founder Chris Rivera ...
... REDWOOD CITY, Calif., Oct. 4 Genomic Health,Inc. ... Scott, Ph.D., Genomic,Health,s Chairman and Chief Executive Officer, ... Francisco, CA on October 11, 2007 at 3:00 ... subsequently archived webcast of the,presentation, visit the Investor ...
Cached Biology Technology:The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies 2The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies 3The Food Allergy & Anaphylaxis Network (FAAN) and Verus Pharmaceuticals Work Together to Raise Awareness of Food Allergies 4Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event 2Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event 3Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event 4Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event 5Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event 6Genomic Health to Present at BIO InvestorForum 2007 2
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... "big data," a single computer cannot always find the ... distributed across a cluster of computers that analyze a ... mine your web history to present you with targeted ... favorite book or movie. But big data is about ... monitoring brain activity are generating unprecedented quantities of information. ...
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New tools help neuroscientists analyze 'big data' 2New tools help neuroscientists analyze 'big data' 3New tools help neuroscientists analyze 'big data' 4New tools help neuroscientists analyze 'big data' 5Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... a "backup" brain region springs into action to compensate for ... Their finding offers new insight into how the brains of ... recovery of movement. , Jacinta O'Shea and colleagues at the ... 2007 issue of the journal Neuron, published by Cell Press. ...
... the University of Rhode Island have demonstrated a new way ... of protein that acts like a nanosyringe to deliver “tags?or ... of the National Academy of Sciences. , The researchers show ... be injected into the abdomen of a mouse, find its ...
... survey of lizards on islands around the world has ... observed: Animals on islands are much more abundant than ... longstanding observation, the study signals an alarm for island ... climate change may have devastating consequences for lizards and ...
Cached Biology News:How the brain's backup system compensates for stroke 2pHLIP, a novel technology to locate and treat tumors 2Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems 2Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems 3
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
Biology Products: